BioMarin Pharmaceutical Inc
BMRN Details
BioMarin Pharmaceutical Inc. (BioMarin) (NASDAQ: BMRN) is a biotechnology company that develops and commercializes therapies that address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.
Financial Results
- BMRN posted total revenues for Q2 FY 2023 of $595.3 Mn, exhibiting a rise of 12% as compared to the same period in 2022.
- GAAP and Non-GAAP Net Income rose $28.3 Mn and $28.4 Mn, respectively for Q2 FY 2023 as compared to the same period in 2022. The higher net income was mainly because of increased gross profit and interest income, partially offset by the higher spend in R&D programs in order to support early-stage research as well as clinical activities, and higher selling, general and administrative expenses because of higher foreign currency losses and to support the commercial launches of VOXZOGO and ROCTAVIAN.
Outlook
For FY 2023, the company is expecting total revenues of $2,375 Mn- $2,500 Mn and enzyme product revenues of between $1,700 Mn- $1,850 Mn. Its gross profit is expected to be between 77.5%- 79% and GAAP net income is expected to be between $155 Mn - $205 Mn.
Key Risks
Weak global growth, Inflation, etc. are some of the risks BMRN is exposed to.
EV/Sales Relative Valuation (Illustrative)
Stock Recommendation
Considering the resistance around the range, current trading levels, risks associated, and volatile market conditions on the back of rising interest rates, a ‘Sell’ rating is assigned to the “BMRN” at the current market price of USD 94.60 (as of 30 August 2023, at 07:15 am PDT).
Technical Overview:
Daily Price Chart
BMRN is a part of Global Big Money Portfolio.
Markets are trading in a highly volatile zone currently due to certain macro-economic and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.
Note 1: Past performance is neither an indicator nor a guarantee of future performance.
Note 2: The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services. Please note past performance is neither an indicator nor a guarantee of future performance.
Please also read our Terms & Conditions and Financial Services Guide for further information.
Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.